Big4Bio

@big4bio

Subscribe FREE to , , , and newsletters that cover biotech's *Big 4*, the world's top life science hubs

Vrijeme pridruživanja: prosinac 2013.

Tweetovi

Blokirali ste korisnika/cu @big4bio

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @big4bio

  1. Prikvačeni tweet
    14. ožu 2019.
    , , i još njih 3
    Poništi
  2. prije 4 sata
    Poništi
  3. proslijedio/la je Tweet

    Some great insight from our , Tania Zieja, at the CFO 3.0 panel last week in . Tania and the other panelist discuss how times are changing with the implementation of new and what that means for their roles as CFO:

    Poništi
  4. proslijedio/la je Tweet
    prije 6 sati

    In response to Canada's new regs, 74% of execs assert there will be a significant negative impact on product launches, commercialization & supply. This new survey further proves the impact of on & industry

    Poništi
  5. prije 5 sati

    Price increases from some of the biggest companies have fallen from 12% in 2014 to 5.2% in 2019.

    Poništi
  6. proslijedio/la je Tweet

    Can scientists use to find a drug to fight the ? Depends on your definition of AI. Check out 's story for about a new report suggesting that baricitinib, a kinase inhibitor, might slow the viruses entry into cells.

    Poništi
  7. prije 14 sati

    GlaxoSmithKline CEO Emma Walmsley is triggering a New GSK R&D makeover, while shedding dermatology -

    Poništi
  8. 4. velj

    Investment in neglected disease R&D has grown for the third year, now totalling $4 billion.

    Poništi
  9. proslijedio/la je Tweet
    4. velj

    💡PANEL SPOTLIGHT💡 Catch the Market Performance and IPO Class of 2020 panel at and examine whether the overall market will experience a cooling off period in 2020 or if we are at the beginning of a long-term growth cycle. View the complete program⬇️

    Poništi
  10. proslijedio/la je Tweet
    4. velj

    Do not miss out on the event of the year and register for your Annual Dinner table today!

    Poništi
  11. 4. velj
    Poništi
  12. proslijedio/la je Tweet
    4. velj

    Passage ended 2019 with $158.9 million in the bank and now expects its phase 1/2 gangliosidosis trial to kick off in the second half of 2020, with trials for the dementia and Krabbe candidates to follow in the first half of 2021

    Poništi
  13. 4. velj

    The development of safer opiods face a few different obstacles.

    Poništi
  14. proslijedio/la je Tweet
    3. velj
    Poništi
  15. proslijedio/la je Tweet
    3. velj

    The latest from the Boston Globe, featuring alumni Audion, highlights the challenges gene therapy and regenerative medicine companies in hearing loss are facing despite promising technologies, funding, and big demand. Read more:

    Poništi
  16. 3. velj
    Poništi
  17. proslijedio/la je Tweet
    2. velj

    Download your copy of BIO’s first annual report on and in at

    Poništi
  18. proslijedio/la je Tweet
    3. velj

    As noted, "The Greater Philadelphia region has ...come into its own in the life science world!" Check out their year-in-review report here:

    Poništi
  19. 31. sij
    Poništi
  20. 31. sij

    "There is no way to have this innovative, different way of thinking, solving problems that have never been solved before, if everyone is the same, either by background, or gender or ethnicity."

    Poništi
  21. 31. sij
    Prikaži ovu nit
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·